Đặc điểm lâm sàng và kết quả điều trị nhiễm nấm da tại Bệnh viện Trường Đại học Y Dược Cần Thơ

Dermatophytosis, a superficial fungal infection caused by dermatophytes such as Trichophyton, Microsporum, and Epidermophyton, remains a prevalent health concern globally. While typically not life-threatening, its chronic nature, diverse clinical manifestations, and high recurrence rates significantly impair patients' quality of life and pose considerable challenges in accurate diagnosis and effective treatment. Recognizing these complexities, this study aims to investigate the clinical characteristics and evaluate the treatment outcomes of dermatophytosis among patients attending Can Tho University of Medicine and Pharmacy Hospital in 2024-2025. This research is crucial for enhancing our understanding of the disease epidemiology and optimizing therapeutic strategies in the regional context.

Medical professionals, particularly dermatologists, general practitioners, public health researchers, and medical students interested in superficial fungal infections and treatment outcomes.

This study investigates the clinical characteristics and treatment outcomes of dermatophytosis among 60 patients at Can Tho University of Medicine and Pharmacy Hospital from 2024-2025. Dermatophytosis, caused by superficial fungal organisms like Trichophyton, Microsporum, and Epidermophyton, is a common condition that, despite not being fatal, significantly impacts quality of life due to its diverse clinical presentations and high recurrence rates, making diagnosis and treatment challenging. Employing a descriptive cross-sectional analytical design, the research identified a mean patient age of 34.6 ± 17.4 years, with a male predominance (60%) and a significant proportion being students. The most common affected areas were the head, face, and neck, with lesions often being disseminated across multiple sites. Clinically, pruritus and erythema were the most frequently reported symptoms, and skin lesions typically appeared as oval or round shapes. Following two weeks of itraconazole treatment, a notable improvement was observed in symptoms such as pruritus, erythema, vesicles, and scaling. By the fourth week, cure rates for erythema and pruritus reached 84.8-87%, while scaling and vesicles showed 88.8-90% resolution. The non-response rate was consistently low and decreasing. These findings underscore that itraconazole, whether used alone or in combination, provides a sustainable and highly effective treatment regimen for dermatophytosis, leading to significant symptomatic improvement over time. The study contributes valuable data for enhancing clinical practice and patient management in the region.